drugset
Drugs / BXCL701
last change Jul 2026 re-read 3 minutes ago

BXCL701

Peptide

Developed for
acute myeloid leukemia · myelodysplastic syndrome with excess blasts-2 · pancreatic ductal adenocarcinoma
Investigated by
BioXcel Therapeutics Inc · Eric Stephen Winer, MD · Georgetown University · Merck Sharp & Dohme LLC

Trials 2

today NCT05558982 · Ph 2 NCT05703542 · Ph 1
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05703542 Feb 2023 → Mar 2026 overdue acute myeloid leukemia, myelodysplastic syndrome with excess blasts-2 Eric Stephen Winer, MD Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT05558982 Aug 2023 → Dec 2025 overdue pancreatic ductal adenocarcinoma Georgetown University Active not recruiting No outcome recorded

Press releases naming this drug 28 releases

DateIssuerRelease
2024-04-24 BioXcel Therapeutics Inc BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting bioxceltherapeutics.com ↗
2024-02-12 BioXcel Therapeutics Inc BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC) bioxceltherapeutics.com ↗
2024-02-06 BioXcel Therapeutics Inc BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA® bioxceltherapeutics.com ↗
2023-11-08 BioXcel Therapeutics Inc BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype bioxceltherapeutics.com ↗
2023-10-10 BioXcel Therapeutics Inc BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer bioxceltherapeutics.com ↗
2023-02-13 BioXcel Therapeutics Inc BioXcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer; to be Presented at 2023 ASCO Genitourinary Cancers Symposium bioxceltherapeutics.com ↗
2023-02-08 BioXcel Therapeutics Inc BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Company’s Investigational, Oral Innate Immune Activator for Rare Form of Prostate Cancer bioxceltherapeutics.com ↗
2023-01-11 BioXcel Therapeutics Inc BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer bioxceltherapeutics.com ↗
2022-02-14 BioXcel Therapeutics Inc BioXcel Therapeutics Presents Positive Data from Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2022 ASCO Genitourinary Cancers Symposium bioxceltherapeutics.com ↗
2021-10-18 BioXcel Therapeutics Inc BioXcel Therapeutics Announces Expansion of Phase 2 Trial of BXCL701 in De Novo and Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer bioxceltherapeutics.com ↗
2021-09-15 BioXcel Therapeutics Inc BioXcel Therapeutics Presents Results from Ongoing Phase 2 Trial of BXCL701 in Combination with KEYTRUDA® in Aggressive Forms of Prostate Cancer at ESMO bioxceltherapeutics.com ↗
2021-09-12 BioXcel Therapeutics Inc BioXcel Therapeutics to Present Updates from Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2021 ESMO Congress bioxceltherapeutics.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as BXCL701 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05703542 ↗
1

NCT05558982 ↗
Modality Peptide “BXCL701 is a synthetic dipeptide that is in tablet form and is taken by mouth.” NCT05703542 ↗
Route Oral “orally” NCT05558982 ↗